Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Pancreatic Cancer: Page 2
AI predicts which patients to test for pancreatic cancer
The researchers matched 1,378 patients in the U.K. who developed pancreatic cancer with four people of the same age and sex who developed another type of cancer. They then created a model to predict an individual's cancer risk using the patients' electronic health records data from general physician appointments. The data included the patients' symptoms, diseases, and medications up to two years before their cancer diagnosis.
July 5, 2020
Caris to highlight precision medicine at ASCO 2020
The research to be presented includes results from studies of multiple cancer types, such as colorectal, pancreatic, lung, and breast cancer, according to the firm.
May 11, 2020
Blood test bolsters imaging for staging pancreatic cancer
The researchers evaluated circulating cell-free DNA using quantitative polymerase chain reaction (qPCR) technology in patients with PDAC, which they noted is the most common type of pancreatic cancer and the third leading cause of cancer-related death in the U.S., with very low survival rates. Diagnosis and staging are currently done with ultrasound-guided biopsy, computed tomography, and magnetic resonance imaging.
April 15, 2020
How to manage genetic testing of pancreatic cancer patients
The National Comprehensive Cancer Network recently recommended germline testing for all people newly diagnosed with pancreatic ductal adenocarcinoma (PDAC). Also, the American Society of Clinical Oncology has issued a clinical opinion advising risk assessment and consideration of germline testing for all patients newly diagnosed, Dr. Eileen O'Reilly, an oncologist at Memorial Sloan Kettering Cancer Center, and colleagues observed. But opinions on what, exactly, to test for have been divided, and guidance has been lacking, they suggested in JAMA Oncology.
February 13, 2020
Top 10 stories for 2019 | Pancreatic cancer mutations | Is genetic testing up to scratch?
Dear LabPulse Member,
January 6, 2020
Lynparza PARP approval opens door to more pancreatic cancer testing
The targeted poly (ADP-ribose) polymerase (PARP) inhibitor Lynparza was approved as a first-line maintenance treatment for germline BRCA-mutated metastatic pancreatic cancer, Merck and AstraZeneca announced on December 30. The "maintenance" approval covers those who respond to platinum-based chemotherapy and have not progressed. On the same day, Myriad Genetics announced the FDA approval of its BRACAnalysis CDx for use as a companion diagnostic to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with Lynparza.
January 1, 2020
Most Popular
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Quest Diagnostics offers suite of services for transplant patients and living donors
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Rapid nirmatrelvir treatment in study reduced long-COVID risk
Bluestar bolsters blood test with breast, pancreatic cancer data
The company has developed a platform for genome-wide profiling of the biomarker 5-hydroxymethylcytosine (5hmC) in cell-free DNA (cfDNA), which it hopes to apply across multiple cancers.
September 16, 2019
Invitae provides free testing to pancreatic cancer patients
Patients must meet criteria in specific clinical areas where genetic testing is underutilized to be eligible for testing. Professional guidelines recommend genetic testing for all pancreatic cancer patients to guide treatment choices and evaluate eligibility for clinical trials, the company noted in a statement.
September 8, 2019
Thrive lifts off with multicancer liquid biopsy test
Developed by Johns Hopkins University researchers and licensed exclusively to Thrive, CancerSEEK tests DNA and protein in the blood and is designed for use in primary care settings. The test has breakthrough device designation with the U.S. Food and Drug Administration for use in detecting proteins and mutations associated with ovarian and pancreatic cancers.
May 29, 2019
Previous Page
Page 2 of 2
